Congratulations on the recovery and continued response to Keytruda. This brings to mind some research I've read in the last month or so concerning turning tumors that are infiltrated with immune cells and resistant to them had high activity of the gene monoamine oxidase A. This is the gene that produces a protein that is the target of MAOI drugs. They found that if they could block this, tumors became more susceptible to the infiltrated Immune system T-cells. So apparently MAO-A is another immune checkpoint. Nice thing about all this is that MAO-A is the target of old Anti-Depressants that have been on the market since the 50's and have been supplanted by newer anti-depressants. But the old ones are still around. They found by treating Mice with MAOI's such as phenelzine, clorgyline, or Mocolobemide the tumors grew more slowly. When mice were treated with prochloroperazine and a PD-L1 checkpoint inhibitor, it outperformed either therapy alone at shrinking tumors! So we might see oncologists prescribing old anti-depressants w PL1 checkpoint inhibitors in the future. These mouse studies where performed on Colon, and Melanoma tumors in Mice. UCLA is doing a clinical trial using phenelzine in prostate cancer patients and have reported that they saw PSA levels drop in 11 out of 20 participants.
Users browsing this forum: No registered users and 7 guests